See more : SEIKOH GIKEN Co., Ltd. (6834.T) Income Statement Analysis – Financial Results
Complete financial analysis of Chemed Corporation (CHE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chemed Corporation, a leading company in the Medical – Care Facilities industry within the Healthcare sector.
You may be interested
- MVV Energie AG (MVV1.DE) Income Statement Analysis – Financial Results
- Vivanta Industries Limited (VIVANTA.BO) Income Statement Analysis – Financial Results
- Haymaker Acquisition Corp. III (HYAC) Income Statement Analysis – Financial Results
- Evergreen Products Group Limited (1962.HK) Income Statement Analysis – Financial Results
- KSG Agro S.A. (KSG.WA) Income Statement Analysis – Financial Results
Chemed Corporation (CHE)
About Chemed Corporation
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in two segments, VITAS and Roto-Rooter. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.26B | 2.13B | 2.14B | 2.08B | 1.94B | 1.78B | 1.67B | 1.58B | 1.54B | 1.46B | 1.41B | 1.43B | 1.36B | 1.28B | 1.19B | 1.15B | 1.10B | 1.02B | 926.48M | 735.34M | 308.87M | 314.18M | 477.12M | 500.69M | 453.60M | 381.30M | 341.70M | 683.80M | 699.20M | 645.00M | 525.10M | 401.00M | 352.30M | 599.40M | 591.80M | 500.60M | 391.00M | 359.50M | 372.70M |
| Cost of Revenue | 1.47B | 1.37B | 1.37B | 1.38B | 1.32B | 1.23B | 1.15B | 1.12B | 1.09B | 1.03B | 1.01B | 1.03B | 970.48M | 906.02M | 834.57M | 810.55M | 767.07M | 730.12M | 651.84M | 507.08M | 182.81M | 186.29M | 295.48M | 295.54M | 269.80M | 230.50M | 206.00M | 436.50M | 457.40M | 422.60M | 344.90M | 259.60M | 227.00M | 315.20M | 309.00M | 244.20M | 162.30M | 147.40M | 152.90M |
| Gross Profit | 796.55M | 765.09M | 769.80M | 701.39M | 617.43M | 554.00M | 516.19M | 461.45M | 455.78M | 421.61M | 404.52M | 396.72M | 385.49M | 374.53M | 355.66M | 338.39M | 332.99M | 288.46M | 274.64M | 228.26M | 126.06M | 127.89M | 181.64M | 205.15M | 183.80M | 150.80M | 135.70M | 247.30M | 241.80M | 222.40M | 180.20M | 141.40M | 125.30M | 284.20M | 282.80M | 256.40M | 228.70M | 212.10M | 219.80M |
| Gross Profit Ratio | 35.18% | 35.84% | 35.98% | 33.73% | 31.85% | 31.08% | 30.97% | 29.26% | 29.53% | 28.95% | 28.62% | 27.74% | 28.43% | 29.25% | 29.88% | 29.45% | 30.27% | 28.32% | 29.64% | 31.04% | 40.81% | 40.71% | 38.07% | 40.97% | 40.52% | 39.55% | 39.71% | 36.17% | 34.58% | 34.48% | 34.32% | 35.26% | 35.57% | 47.41% | 47.79% | 51.22% | 58.49% | 59.00% | 58.98% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 322.92M | 358.73M | 366.73M | 330.22M | 305.71M | 270.21M | 276.65M | 243.57M | 237.82M | 220.12M | 212.52M | 208.66M | 202.26M | 201.96M | 197.43M | 175.33M | 184.06M | 161.18M | 151.67M | 138.29M | 105.90M | 95.51M | 146.71M | 148.23M | 136.90M | 113.40M | 100.90M | 197.20M | 190.60M | 177.60M | 143.90M | 117.00M | 107.70M | 226.40M | 211.60M | 194.20M | 169.50M | 159.10M | 162.50M |
| Selling & Marketing | 72.20M | 68.60M | 62.10M | 54.40M | 49.50M | 47.00M | 40.90M | 37.20M | 36.40M | 32.80M | 31.00M | 29.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 395.12M | 358.73M | 366.73M | 330.22M | 305.71M | 270.21M | 276.65M | 243.57M | 237.82M | 220.12M | 212.52M | 208.66M | 202.26M | 201.96M | 197.43M | 175.33M | 184.06M | 161.18M | 151.67M | 138.29M | 105.90M | 95.51M | 146.71M | 148.23M | 136.90M | 113.40M | 100.90M | 197.20M | 190.60M | 177.60M | 143.90M | 117.00M | 107.70M | 226.40M | 211.60M | 194.20M | 169.50M | 159.10M | 162.50M |
| Other Expenses | 60.87M | 62.86M | 60.04M | -18.51M | 54.34M | 287.00K | 8.43M | 2.06M | -270.00K | 3.19M | 4.94M | 3.66M | 29.50M | 29.04M | 31.89M | 27.51M | 26.18M | 22.30M | 43.58M | 31.87M | 12.05M | 13.59M | 16.11M | 23.45M | 20.10M | 17.30M | 15.20M | 18.80M | 18.20M | 15.80M | 13.10M | 9.20M | 8.10M | 23.10M | 21.70M | 19.30M | 16.50M | 14.60M | 13.90M |
| Operating Expenses | 455.99M | 421.59M | 426.77M | 311.71M | 360.05M | 310.37M | 403.16M | 282.70M | 271.32M | 253.19M | 244.91M | 240.30M | 231.76M | 231.01M | 229.32M | 205.54M | 210.24M | 183.49M | 195.25M | 170.16M | 117.95M | 109.10M | 162.82M | 171.68M | 157.00M | 130.70M | 116.10M | 216.00M | 208.80M | 193.40M | 157.00M | 126.20M | 115.80M | 249.50M | 233.30M | 213.50M | 186.00M | 173.70M | 176.40M |
| Cost & Expenses | 1.92B | 1.79B | 1.80B | 1.69B | 1.68B | 1.54B | 1.55B | 1.40B | 1.36B | 1.29B | 1.25B | 1.27B | 1.20B | 1.14B | 1.06B | 1.02B | 977.30M | 913.61M | 847.09M | 677.24M | 300.76M | 295.38M | 458.30M | 467.22M | 426.80M | 361.20M | 322.10M | 652.50M | 666.20M | 616.00M | 501.90M | 385.80M | 342.80M | 564.70M | 542.30M | 457.70M | 348.30M | 321.10M | 329.30M |
| Interest Income | 6.27M | 355.00K | 377.00K | 757.00K | 513.00K | 671.00K | 427.00K | 383.00K | 281.00K | 0.00 | 847.00K | 809.00K | 426.00K | 444.00K | 423.00K | 743.00K | 3.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.11M | 4.58M | 1.87M | 2.36M | 4.54M | 4.99M | 4.27M | 3.72M | 3.65M | 8.22M | 15.04M | 14.72M | 13.89M | 11.96M | 11.60M | 5.99M | 11.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 60.87M | 59.17M | 59.05M | 56.58M | 45.21M | 38.86M | 35.63M | 34.64M | 33.50M | 33.07M | 32.39M | 30.52M | 29.50M | 29.04M | 27.90M | 27.51M | 26.57M | 23.80M | 23.34M | 20.18M | 12.81M | 14.36M | 24.12M | 23.45M | 20.10M | 17.30M | 15.20M | 18.80M | 18.20M | 15.80M | 13.10M | 9.20M | 8.10M | 23.10M | 21.70M | 19.30M | 16.50M | 14.60M | 13.90M |
| EBITDA | 414.34M | 393.44M | 411.23M | 454.93M | 311.35M | 283.45M | 156.81M | 215.41M | 217.27M | 200.62M | 162.17M | 191.06M | 183.94M | 174.83M | 160.12M | 155.84M | 138.47M | 126.28M | 99.68M | 78.14M | 18.60M | 27.72M | 37.23M | 52.94M | 46.90M | 37.40M | 34.80M | 29.20M | 51.20M | 44.80M | 36.30M | 24.40M | 17.60M | 57.80M | 71.20M | 62.20M | 59.20M | 53.00M | 57.30M |
| EBITDA Ratio | 18.30% | 18.43% | 19.22% | 21.88% | 16.06% | 15.90% | 9.45% | 13.69% | 14.12% | 14.06% | 13.99% | 13.38% | 13.51% | 13.48% | 12.96% | 13.56% | 14.83% | 12.40% | 13.80% | 12.47% | 8.25% | 16.01% | 13.92% | 10.07% | 7.91% | 4.88% | 4.62% | 2.21% | 4.96% | 5.47% | 3.87% | 2.47% | 0.62% | 9.19% | 11.41% | 11.95% | 14.32% | 17.80% | 13.31% |
| Operating Income | 340.57M | 343.50M | 343.04M | 389.68M | 257.38M | 243.63M | 113.04M | 178.75M | 184.46M | 168.42M | 133.39M | 156.42M | 153.73M | 143.52M | 126.35M | 132.86M | 122.76M | 104.98M | 79.38M | 58.11M | -7.72M | -1.55M | 18.82M | 33.47M | 26.80M | 20.10M | 19.60M | 31.30M | 33.00M | 29.00M | 23.20M | 15.20M | 9.50M | 34.70M | 49.50M | 42.90M | 42.70M | 38.40M | 43.40M |
| Operating Income Ratio | 15.04% | 16.09% | 16.04% | 18.74% | 13.28% | 13.67% | 6.78% | 11.34% | 11.95% | 11.56% | 9.44% | 10.94% | 11.34% | 11.21% | 10.62% | 11.56% | 11.16% | 10.31% | 8.57% | 7.90% | -2.50% | -0.49% | 3.94% | 6.68% | 5.91% | 5.27% | 5.74% | 4.58% | 4.72% | 4.50% | 4.42% | 3.79% | 2.70% | 5.79% | 8.36% | 8.57% | 10.92% | 10.68% | 11.64% |
| Total Other Income/Expenses | 9.80M | -13.82M | 7.28M | 6.31M | 4.23M | -4.03M | 3.88M | -1.70M | -4.33M | -5.67M | -9.57M | -12.94M | -13.17M | -9.69M | -5.73M | -10.51M | -20.92M | -14.70M | -24.73M | -21.02M | 7.67M | -18.42M | -29.15M | -2.54M | 4.20M | 12.00M | 8.30M | 11.00M | 3.00M | -3.50M | 3.20M | 5.60M | 6.90M | -7.70M | -8.10M | -8.60M | -5.60M | -22.60M | -2.90M |
| Income Before Tax | 350.37M | 329.68M | 350.31M | 395.99M | 261.61M | 239.60M | 116.92M | 177.05M | 180.13M | 162.75M | 123.83M | 145.82M | 140.56M | 133.83M | 120.62M | 122.35M | 101.84M | 90.28M | 57.28M | 37.09M | 1.25M | -1.28M | -10.06M | 33.25M | 31.00M | 32.10M | 27.90M | 53.60M | 36.00M | 25.50M | 26.40M | 20.80M | 16.40M | 27.00M | 41.40M | 34.30M | 37.10M | 15.80M | 40.50M |
| Income Before Tax Ratio | 15.47% | 15.44% | 16.38% | 19.04% | 13.50% | 13.44% | 7.01% | 11.23% | 11.67% | 11.18% | 8.76% | 10.20% | 10.37% | 10.45% | 10.13% | 10.65% | 9.26% | 8.86% | 6.18% | 5.04% | 0.40% | -0.41% | -2.11% | 6.64% | 6.83% | 8.42% | 8.17% | 7.84% | 5.15% | 3.95% | 5.03% | 5.19% | 4.66% | 4.50% | 7.00% | 6.85% | 9.49% | 4.39% | 10.87% |
| Income Tax Expense | 77.86M | 80.06M | 81.76M | 76.52M | 41.69M | 34.06M | 18.74M | 68.31M | 69.85M | 63.44M | 46.60M | 56.52M | 54.58M | 52.00M | 46.58M | 50.24M | 39.06M | 32.56M | 19.58M | 13.80M | 4.75M | 6.85M | -3.36M | 12.66M | 11.30M | 12.20M | 10.80M | 21.90M | 15.60M | 11.00M | 9.30M | 6.50M | 5.40M | 10.40M | 15.20M | 13.70M | 16.70M | 9.00M | 18.60M |
| Net Income | 272.51M | 249.62M | 268.55M | 319.47M | 219.92M | 205.54M | 98.18M | 108.74M | 110.27M | 99.32M | 77.23M | 89.30M | 85.98M | 81.83M | 73.78M | 71.02M | 63.98M | 50.65M | 35.82M | 27.51M | -3.44M | -1.81M | -10.38M | 20.58M | 19.70M | 19.90M | 30.30M | 32.30M | 23.10M | 43.90M | 19.50M | 15.70M | 52.90M | 16.60M | 26.20M | 21.90M | 20.40M | 36.80M | 21.90M |
| Net Income Ratio | 12.03% | 11.69% | 12.55% | 15.36% | 11.34% | 11.53% | 5.89% | 6.90% | 7.14% | 6.82% | 5.46% | 6.24% | 6.34% | 6.39% | 6.20% | 6.18% | 5.82% | 4.97% | 3.87% | 3.74% | -1.11% | -0.58% | -2.17% | 4.11% | 4.34% | 5.22% | 8.87% | 4.72% | 3.30% | 6.81% | 3.71% | 3.92% | 15.02% | 2.77% | 4.43% | 4.37% | 5.22% | 10.24% | 5.88% |
| EPS | 18.11 | 16.72 | 17.14 | 20.02 | 13.77 | 12.80 | 6.11 | 6.64 | 6.54 | 5.79 | 4.24 | 4.72 | 4.19 | 3.62 | 3.29 | 3.08 | 2.61 | 1.94 | 1.40 | 1.14 | -0.17 | -0.09 | -0.53 | 1.01 | 0.93 | 0.99 | 1.52 | 1.65 | 1.18 | 2.23 | 1.00 | 0.80 | 2.64 | 0.80 | 1.31 | 1.19 | 1.14 | 2.06 | 1.25 |
| EPS Diluted | 17.93 | 16.53 | 16.85 | 19.48 | 13.31 | 12.23 | 5.86 | 6.48 | 6.33 | 5.57 | 4.16 | 4.62 | 4.10 | 3.55 | 3.24 | 3.04 | 2.55 | 1.90 | 1.36 | 1.12 | -0.17 | -0.09 | -0.53 | 1.00 | 0.93 | 0.99 | 1.51 | 1.63 | 1.18 | 2.23 | 1.00 | 0.80 | 2.64 | 0.80 | 1.27 | 1.14 | 1.08 | 1.80 | 1.14 |
| Weighted Avg Shares Out | 15.05M | 14.93M | 15.67M | 15.96M | 15.97M | 16.06M | 16.06M | 16.38M | 16.87M | 17.17M | 18.20M | 18.92M | 20.52M | 22.59M | 22.45M | 23.06M | 24.52M | 26.12M | 25.55M | 24.12M | 19.85M | 19.72M | 19.43M | 19.67M | 20.94M | 20.12M | 19.88M | 19.58M | 19.72M | 19.71M | 19.60M | 19.63M | 20.08M | 20.75M | 20.08M | 18.48M | 17.89M | 17.86M | 17.59M |
| Weighted Avg Shares Out (Dil) | 15.20M | 15.10M | 15.94M | 16.40M | 16.53M | 16.80M | 16.74M | 16.79M | 17.42M | 17.84M | 18.59M | 19.34M | 20.95M | 23.03M | 22.74M | 23.37M | 25.08M | 26.67M | 26.30M | 24.64M | 19.91M | 19.77M | 19.43M | 19.85M | 21.03M | 20.20M | 20.03M | 19.82M | 19.72M | 19.71M | 19.60M | 19.63M | 20.08M | 20.75M | 20.63M | 19.30M | 18.98M | 20.44M | 19.30M |
Here's Why You Should Retain Chemed (CHE) Stock for Now
Investors are optimistic about Chemed (CHE), backed by the strong performance of the VITAS Healthcare and Roto-Rooter segments.
VITAS Completes the Previously Announced Purchase of Assets of Covenant in Florida and Alabama
CINCINNATI--(BUSINESS WIRE)--VITAS Healthcare Corporation, a wholly-owned subsidiary of Chemed Corporation (“Chemed”) (NYSE: CHE) announced the completion of the previously announced purchase of all hospice operations and an assisted living facility from Covenant Health and Community Services, Inc. d/b/a/ Covenant Care...
Chemed (CHE) Up 2.5% Since Last Earnings Report: Can It Continue?
Chemed (CHE) reported earnings 30 days ago. What's next for the stock?
Chemed (CHE) Reaches a New 52-Week High: What's Driving It?
Investors are optimistic about Chemed (CHE) on strong performance across the VITAS and Roto-Rooter segments.
Chemed's (CHE) VITAS Segment Inks New Deal With Covenant Care
Chemed's (CHE) VITAS segment is set to acquire the hospice assets of Covenant Care in Florida and Alabama.
VITAS To Buy Hospice Assets of Covenant Care in Florida and Alabama
CINCINNATI--(BUSINESS WIRE)--VITAS Healthcare Corporation, a wholly-owned subsidiary of Chemed Corporation (“Chemed”) (NYSE: CHE), announced it entered into an agreement on March 12, 2024 to acquire all hospice operations and an assisted living facility from Covenant Health and Community Services, Inc....
Chemed Corporation to Present at the Oppenheimer 34th Annual Healthcare Conference
CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) today announced that it will deliver a virtual presentation at the Oppenheimer 34th Annual Healthcare Conference on Tuesday, March 12, 2024, at approximately 12:00 p.m. (ET). The virtual presentation will be webcast live and can be...
Is Chemed (CHE) a Solid Growth Stock? 3 Reasons to Think "Yes"
Chemed (CHE) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ADUS vs. CHE: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Outpatient and Home Healthcare sector have probably already heard of Addus HomeCare (ADUS) and Chemed (CHE). But which of these two companies is the best option for those looking for undervalued stocks?
Chemed (CHE) Q4 Earnings Surpass Estimates, Margins Expand
Chemed's (CHE) fourth-quarter 2023 performance reflects an improvement in VITAS' operational metrics.
Source: https://incomestatements.info
Category: Stock Reports